Full size table Table 2 Recent agents targeting HER2 in different cancer Full size table Gastric cancer Antibodies Gastric cancer is a prevalent malignancy that ranks fifth in terms of global incidence. Regrettably, the prognosis for advanced or metastatic gastric cancer remains dismal, with a mere ...
HER2 is expressed at excessive levels in 20% to 30% of breast cancers because of gene amplification. It is one of the most reliable biomarkers identified to date; the overexpression of HER2 is a hallmark of an aggressive form of the disease (2). Two types of agents are currently available...
近日,来自复旦大学附属肿瘤医院邵志敏教授、肖毅副研究员团队在Cell Reports Medicine杂志发表了一篇题为Multimodal integration using a machine learning approach facilitates risk stratification in HR+/HER2- breast cancer的研究论文。 该研究...
Breast cancer: dual HER2 blockade may reduce need for anthracyclinesBreast cancer: dual HER2 blockade may reduce need for anthracyclinesIt appears that a combination of two anti-HER2 therapies and three months of paclitaxel weekly may bdoi:10.1097/01.OTU.0000411005.87666.4dCarlsonRobert...
A and B: Controls confirming accuracy of truncated HER2 detection in representative human breast cancer cases and cell lines. A: Breast cancer case expressing a predominantly full-length receptor (left panel) showing evidence for decreased ECD/ICD ratio only in single cells, and breast cancer case...
Sequencing of targeted therapies in HER2-positive metastatic breast cancer. PowerPoint slide Full size image Hormone receptor positive and HER2+ MBC About 50% of the HER2+ patients are also hormone receptor positive (HR+). There are important biological differences underlying pure HER2+/hormone rece...
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. At a glance Originator BioLife Science; Pevion Biotech Developer Imugene; Pe...
https://www.nejm.org/doi/full/10.1056/NEJMoa2203690 [2]Goto K,et al.Trastuzumab deruxtecan in patients with HER2-mutant metastatic non–small-cell lung cancer: Primary results from the randomized, phase II DESTINY-...
Full size image Early accumulations of89Zr-DFO-scFv-PEG-Cy5-C’ dots in HER2+ BT-474 tumors could be seen at 2 h p.i. on axial PET images (Fig.3a, axial view); uptake was estimated to be 8.2 ± 1.1 %ID g−1, a value as high as that found for liver (8.3...
Accurate evaluation of human epidermal growth factor receptor type-2 (HER2) status based on core needle biopsy (CNB) specimens is mandatory for identification of patients with primary breast cancer who will benefit from primary systemic therapy with tras